160 likes | 414 Views
The Clinical Investigator's Role in Drug Development. FDA Clinical Investigator Training CourseThe Clinical Trials Transformation Initiative Steering CommitteeNovember 8, 2010. Speakers / Panel. Adam Chasse QuintilesYvonne McCracken, MPH, CCRCCarolinas Research AssociatesCraig WozniakGl
E N D
1. Cosponsored by
FDA’s Office of Critical Path Programs (OCPP)
and
The Clinical Trials Transformation Initiative (CTTI)
FDA’s Clinical Investigator Course
2. The Clinical Investigator’s Role in Drug Development FDA Clinical Investigator Training Course
The Clinical Trials Transformation Initiative Steering Committee
November 8, 2010
3. Speakers / Panel Adam Chasse
Quintiles
Yvonne McCracken, MPH, CCRC
Carolinas Research Associates
Craig Wozniak
GlaxoSmithKline
4. Agenda Opening Remarks
Commitment to Research
Selecting Trial Sites
Successful Site Performance
Site Quality System
Site Monitoring
Question and Answer
5. - Commitment to Research- Selecting Trial Sites Adam R. Chasse
Head, Global Prime Sites
Quintiles
6. “Commitment” – two dimensions Philosophical (macro level)
Protect trial patients’ safety and well-being
Ensure data integrity
Impact is on present and future patients worldwide
Professional (micro level)
Get viable and stay viable as a PI
Grasp and overcome business complexities
Impact is on sustainability of clinical development… and in turn, on patients
7. Site Selection – What Does Industry Need? High quality
PI involvement and accountability
Right patients, right processes
Consistent, proven ability to enroll
Pick the right studies
Plan for and manage delivery
Efficient administrative processes
Budget & contract
IRB & regulatory documents
8. Site Perspective on the Clinical Investigator’s Role in Drug Development Yvonne McCracken, MPH, CCRC
Carolinas Research Associates
9. Recruitment and Retention
Have you determined if there are major challenges to recruitment & retention?
Do you have the population within your practice?
Do you know where to advertise for the population you are seeking?
Does the study require specific retention strategies?
Successful Site Performance
10. Budget
Do you know your true costs?
Staff, printing, mailing, coping, dedicated phone & fax lines
Space for CRC, monitor, study drug, supplies
Advertising/recruitment activities
Long term storage
Computers and software required
Payment terms
Successful Site Performance
11. Time
Study start up – Protocol review, regulatory documents, contract/budget negotiation
Training – GCP and Study specific
Chart reviews and phone screens
Study visits – In/Ex criteria, lab reviews, AE/SAE, IND safety reports
CRF & Query completion
Monitor visits
Successful Site Performance
12. Site Quality SystemSite Monitoring Craig Wozniak
GlaxoSmithKline
13. Site Quality System Framework that extends across investigator accountabilities
Subject protection, data quality / integrity
Collective efforts that enable investigators and staff to safely execute studies in a compliant manner
14. Quality System
15. Site Monitoring Why: Proactively identify and address issues
different techniques used
Establish expectations and discuss concerns
Engage and allocate the time
Aligned Partnership
16. Question and Answer
17. Adam Chasse
Quintiles
Adam.chasse@quintiles.com
Yvonne McCracken, MPH, CCRC
Carolinas Research Associates
ymccracken@carolinasresearch.com
Craig Wozniak
GlaxoSmithKline
craig.a.wozniak@gsk.com
Questions